A non-romantic look at where the modern evidence backs classical practice — and where it doesn't. Read this before paying for any treatment, ours or anyone else's.
Most classical formulations contain 4–30 herbs. Modern pharmacology now confirms multi-target action — anti-inflammatory + adaptogenic + microbiome-modulating + bioavailability-enhancing — that single-molecule drugs rarely match. The classical concept of Yogavahi (synergistic potentiation) has molecular correlates.
Ayurveda treats Ahara (diet), Vihara (lifestyle), and Manasika (mental practice) as three of four therapeutic pillars — equal to Aushadhi (medicine). Modern evidence on diet, sleep, exercise, and stress mirrors this exactly. Most chronic disease responds disproportionately to lifestyle correction; Ayurveda has codified this for 2,000 years.
Prakriti analysis — the classical Vata/Pitta/Kapha typing — has begun to find modern correlates in pharmacogenomics, gut microbiome composition, and circadian endocrine patterns. Whether or not the classical theory is "correct" in modern terms, the practice of individualising treatment routinely outperforms one-size-fits-all approaches.
Conditions where modern RCT data and classical practice converge.
Boswellia (Shallaki) extracts have RCT evidence comparable to celecoxib for pain reduction without GI side effects. Curcumin has multiple meta-analyses supporting NSAID-equivalent efficacy. Pizhichil + Janu-Basti show large clinical effect sizes in Kerala studies.
Shirodhara has been shown to reduce serum cortisol, lower beat-to-beat heart rate variability indicators of stress, and improve PSQI sleep scores. Ashwagandha is among the most-studied adaptogens — multiple double-blind RCTs show reduced cortisol and improved DASS-21 anxiety scores.
Mahatikta Ghrita + Virechana protocol shows PASI score reductions of 60–80% in published Indian studies. Topical curcumin and neem also have modern RCT support. Useful as combined or stand-alone therapy in mild-to-moderate psoriasis.
Triphala, Trikatu, and bitter-aromatic herbs improve gastric motility and reduce visceral hypersensitivity. AYUSH-funded RCTs at AIIA show effect sizes comparable to first-line gastroenterology drugs in functional GI disorders.
Lifestyle + Gymnema (Madhunashini), bitter gourd, and fenugreek show meaningful HbA1c reduction in early disease. Not a substitute for insulin in established T1DM. Strong synergy with metformin in T2DM.
Brahmi (Bacopa) and Ashwagandha have growing RCT evidence as adjuncts. Yoga + pranayama have stronger evidence than most supplements. Shirodhara shows promise in early-stage post-partum depression.
Conditions where Ayurveda should NEVER be substituted for conventional medicine. Beware anyone selling otherwise.
Ayurveda has supportive / palliative value (managing chemo side effects, fatigue, anorexia) but is NOT a substitute for surgery, radiation, or chemotherapy. Any practitioner claiming otherwise should be reported to AYUSH and CCIM.
No replicable evidence for "Ayurvedic cure." Some adjunctive value of Brahmi / Saraswata Churna in concentration; not a therapy substitute. Ignore practitioners promising "reversal".
Sepsis, severe pneumonia, meningitis, severe COVID-19 — antibiotics / antivirals and conventional ICU care first. Ayurveda useful in post-recovery rehab.
Insulin-dependent. Lifelong. Ayurvedic complementary therapy can reduce insulin units modestly, but never replace.
Acute abdomen, fractures, ectopic pregnancy, MI, stroke — call 108. Sushruta was a surgeon; he would have called modern surgeons too.
Ayurveda, practised by a qualified BAMS / MD doctor in a regulated centre, is excellent at chronic disease, mental health, dermatology, and lifestyle-driven metabolic disorders. It is a complement to — not a replacement for — modern medicine in acute, infectious, oncological, and surgical care. AyurConnect's job is to help you find good practitioners for the first category and to keep you from being misled about the second.